Mediso Launches TheraMAX SPECT/CT Scanner

Summary: Mediso introduced the AnyScan TRIO SPECT/CT, TheraMAX scanner at the European Association of Nuclear Medicine meeting, designed for theranostic imaging and radioisotope therapies, with the first installation at University Hospital Regensburg, Germany.

Key Takeaways

• Theranostic Imaging Focus: The TheraMAX scanner is specifically designed for theranostic imaging, supporting a range of radioisotopes including ¹⁷⁷Lu, ²¹²Pb, ¹³¹I, ²²⁵Ac, and others
• Enhanced Sensitivity and Resolution: The system features large-surface detectors and NaI crystals, offering a 300% sensitivity gain and PET-like image quality for whole-body SPECT/CT scans.
• Clinical Impact: The first installation at University Hospital Regensburg is expected to improve diagnostic workflows and enable new clinical research possibilities, according to Professor Dirk Hellwig.

Mediso unveiled the AnyScan TRIO SPECT/CT, TheraMAX scanner at the European Association of Nuclear Medicine (EANM) meeting. The TheraMAX is designed for theranostic imaging, featuring detectors and collimators developed for Targeted Radionuclide Therapies. It supports radioisotopes that emit alpha, beta, and high-energy gamma photons such as ¹⁷⁷Lu, ²¹²Pb, ¹³¹I, ²²⁵Ac, and others

The TheraMAX is equipped with three large-surface detectors (up to five times larger than 12-detector CZT systems) that surround the patient completely (360°). The 15.9 mm thick NaI crystals ensure improved sensitivity for high-energy photons, while the high-density sensor arrangement (123 PMT per detector head) allows for high spatial resolution, leading to PET-like image quality in all nuclear medicine applications.

Boosting Sensitivity for Whole-Body SPECT/CT

According to Mediso, the 300% sensitivity gain compared to conventional dual-detector systems enables whole-body ²²⁵Ac SPECT/CT for theranostic imaging. This extreme system response also allows for ultra-fast quantitative total-body SPECT/CT scans with ^99mTc and low-energy high-resolution, high-sensitivity collimators . The integrated CT provides three options: low-dose diagnostic scans, an ultra-low dose protocol for attenuation and scatter correction, and “Zero-Dose” imaging using AI-powered synthetic CT, or SyCT.

The first global installation of the TheraMAX scanner is at University Hospital Regensburg, Germany. Following the installation, professor Dirk Hellwig, head of the department of nuclear medicine, stated, “The new scanner will boost our diagnostic and theranostic workflow, leading to better patient care, and it also opens new possibilities in clinical research.”

Istvan Bagaméry, managing director of Mediso, also spoke out about the product launch, commenting: “With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT. The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans.”